Clofazimine 100 mg

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIVTuberculosisTuberculosis, Multidrug-ResistantTuberculosis, Pulmonary

Phase 2

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

TerminatedNCT04311502

National Institute of Allergy and Infectious Diseases (NIAID)HIV, Tuberculosis

Start: 2021-11-05End: 2025-06-24Updated: 2025-08-27

Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruitingNCT05007821

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis, Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary

Start: 2022-08-11End: 2026-03-13Updated: 2025-08-12

Related Papers

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.

2025-09-04